🇺🇸 BMRN — BioMarin Pharmaceutical Inc.

Salud Compra
← Volver

Precio actual

55,66 USD

Máx. histórico

149,13

4124 días

Caída desde máximo

-62,68%

Rango 52 semanas

49,26 – 70,98

Variación hoy

-3,10%

Cierre anterior

57,44

Rango de hoy

52,00 – 56,32

Volumen hoy

4.698.487

Peor caída histórica

-90,58%

01/03/2000 → 27/08/2002

Recuperado en 1960 días

Volatilidad anualizada ⓘ

49,11%

Información
Nombre completo
BioMarin Pharmaceutical Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
3.221
PER ⓘ
150,43 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
91,33 USD (puede no estar actualizado)
Primera cotización
26/07/1999
Precio actualizado
hace 22 horas
Sobre la empresa

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
05/01/2023 107,00 107,59 105,77 106,86 -0,06% 1,70% 1.917.500
04/01/2023 103,69 106,93 102,26 106,92 +6,27% 4,50% 2.741.400
03/01/2023 103,00 103,33 100,52 100,61 -2,78% 2,73% 1.325.500
30/12/2022 101,92 103,57 100,95 103,49 +1,02% 2,57% 910.200
29/12/2022 101,87 103,45 101,67 102,44 +0,69% 1,75% 794.600
28/12/2022 101,98 103,10 101,30 101,74 -0,41% 1,77% 904.500
27/12/2022 104,50 104,85 102,03 102,16 -2,09% 2,70% 760.800
23/12/2022 105,01 105,56 103,87 104,34 -1,25% 1,61% 696.000
22/12/2022 104,61 105,70 103,99 105,66 +0,99% 1,63% 1.335.800
21/12/2022 105,94 107,08 104,53 104,62 -1,58% 2,41% 1.457.800
20/12/2022 105,92 106,75 105,56 106,30 -0,29% 1,12% 997.200
19/12/2022 108,63 108,63 105,81 106,61 -1,86% 2,60% 1.226.000
16/12/2022 107,73 108,92 107,13 108,63 +0,02% 1,66% 2.537.000
15/12/2022 108,00 109,56 106,81 108,61 +0,21% 2,55% 1.614.600
14/12/2022 106,93 109,25 106,51 108,38 +1,21% 2,56% 1.672.100
13/12/2022 107,08 107,91 106,55 107,08 +0,77% 1,27% 1.765.300
12/12/2022 102,25 106,35 102,25 106,26 +3,84% 4,01% 1.856.400
09/12/2022 104,23 104,46 102,28 102,33 -1,97% 2,09% 815.500
08/12/2022 103,99 104,62 103,17 104,39 +0,68% 1,39% 723.000
07/12/2022 101,09 103,94 101,09 103,69 +1,44% 2,82% 1.319.200
06/12/2022 102,97 103,44 101,17 102,22 -1,27% 2,20% 889.400
05/12/2022 105,00 105,34 103,25 103,53 -1,92% 1,99% 994.200
02/12/2022 103,00 106,72 102,75 105,56 +2,47% 3,85% 2.220.200
01/12/2022 100,71 103,06 99,29 103,02 +2,02% 3,74% 2.013.900
30/11/2022 98,51 101,28 97,85 100,98 +3,97% 3,48% 2.493.100
29/11/2022 99,01 99,56 97,00 97,12 -1,56% 2,59% 1.304.300
28/11/2022 97,25 100,30 96,52 98,66 +1,80% 3,89% 2.591.200
25/11/2022 97,46 98,43 96,31 96,92 -0,89% 2,18% 727.800
23/11/2022 95,09 99,74 94,91 97,79 +7,25% 5,08% 4.635.400
22/11/2022 88,99 91,63 88,01 91,18 +3,02% 4,07% 1.620.200